Early symptoms that mimic common ear and sinus conditions often lead to delayed diagnosis.

The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

In today’s Healthy Minute, Dr. Kian Azimian will be discussing the differences between a sinus infection and seasonal ...

Doctors in Central Texas share the latest on flu strains, RSV, stomach viruses and cedar pollen as cold and allergy season ...

Facial swelling can stem from allergies, infections, sinus issues or underlying disease.

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

People with allergic fungal rhinosinusitis taking Dupixent saw significant improvement in congestion and sinus inflammation, ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...

Pharmacists have a seen a marked increase in patients turning to them for treatment for seven of the most common health ...

Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.